Results 81 to 90 of about 13,146 (180)

Antipsychotic Drug Interactions and Short‐Term Mortality Risk in People With Dementia: A National Cohort Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1081-1091, October 2026.
Antipsychotics are often prescribed in the management of behaviors and psychological symptoms of dementia. While the potential harms of antipsychotic use in people with dementia have been established, little is known about the risk associated with antipsychotic drug–drug interactions (DDIs). This study aims to examine the patterns of antipsychotic DDIs
Edward C.Y. Lau, Grace H. Shim, Chin Hang Yiu, Sarah N. Hilmer, Yun‐Hee Jeon, Weisi Chen, Christine Y. Lu, Edwin C.K. Tan   +7 more
wiley   +1 more source

Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1092-1100, October 2026.
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for type 2 diabetes and weight management. However, conflicting evidence from preclinical, clinical, and pharmacovigilance studies suggests potential neuropsychiatric effects.
Maria J. Alfonso Arvez, Sam Wade, Darshna Goordeen, Jenni Ilomäki, Amanda J. Cross, Monica Langiu, George S. Q. Tan   +6 more
wiley   +1 more source

Agomelatine as augmentation therapy with second‐generation antipsychotics for negative symptoms of schizophrenia: An open‐label randomised clinical trial and electroencephalogram‐derived model for treatment response prediction

General Psychiatry, Volume 39, Issue 5, October 2026.
ABSTRACT Background Negative symptoms are a core diagnostic domain of schizophrenia that affect functional outcomes and remain difficult to treat. Agomelatine, a novel antidepressant with melatonin receptor agonism and serotonin 2C receptor antagonism, may have therapeutic potential.
Wanyan Zhou, Fei Liang, Nizhe Chen, Yao Zhang, Xiaoxiao Wang, Xin Li, Daofeng Lu, Fang Guo, Yuan Yao, Jiayu Zhu, Chengjia Shen, Chongze Wang, Peiyun Zhang, Lilan Zhao, Ying Wang, Jinyu Han, Wei Li, Haisu Wu, Peijuan Wang, Qi Yan, Ping Zhang, Qinyu Lv, Zhenghui Yi   +22 more
wiley   +1 more source

Antidepressant use and Parkinson's disease risk: Overall protective effect with drug‐specific variation

General Psychiatry, Volume 39, Issue 5, October 2026.
ABSTRACT Background Antidepressants can cause extrapyramidal side effects, but their impact on Parkinson's disease (PD) risk remains unclear. Aims We aimed to investigate the association between genetic liability to antidepressant use and PD. Methods We examined the causal effect of antidepressant use on PD using Mendelian randomisation (MR) analysis ...
Ancha Baranova, Hongbao Cao, Chenxin Xu, Wenxi Sun, Dongming Liu, Fuquan Zhang   +5 more
wiley   +1 more source

Updated Estimates of Agreement Between Dispensed Medications and Forensic Toxicology in Sweden

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 10, October 2026.
ABSTRACT Purpose To present updated estimates from a nationwide Swedish study comparing dispensed medications with forensic toxicological findings (2006–2013), following re‐evaluation of the toxicology dataset to address periods with non‐uniform analytical detection and inconsistent testing.
Heidi Taipale, Jari Tiihonen, Antti Tanskanen, Jonas Forsman   +3 more
wiley   +1 more source

Mental Health Disorders in End‐Stage Kidney Disease: A Narrative Review of Clinical Considerations for Integrated Management

Hemodialysis International, Volume 30, Issue 4, Page 679-688, October 2026.
ABSTRACT Introduction End stage kidney disease (ESKD) is associated with a high prevalence of depression and anxiety, arising from both biological factors and the psychosocial burden of chronic dialysis care. Approximately 25%–30% of dialysis patients experience clinically significant depressive symptoms when assessed by structured clinical interview ...
Kunal Malhotra, Jordan Fangue‐Nelon, Garima Singh   +2 more
wiley   +1 more source

Mirtazapine for symptom control in refractory gastroparesis

Drug Design, Development and Therapy, 2017
Mark Malamood,1 Aaron Roberts,2 Rahul Kataria,2 Henry P Parkman,2 Ron Schey2 1Department of Internal Medicine, 2Department of Gastroenterology, Temple University Hospital, Philadelphia, PA, USA Introduction: Gastroparesis symptoms can be severe and ...
Malamood M, Roberts A, Kataria R, Parkman HP, Schey R   +4 more
doaj  

Prevalence of Psychotropic Use and Psychotropic Polypharmacy in a Finnish National Cohort of Persons With Intellectual Disabilities

Journal of Intellectual Disability Research, Volume 70, Issue 10, Page 1112-1124, October 2026.
ABSTRACT Background Psychotropic use and psychotropic polypharmacy are common in people with intellectual disabilities, but representative population‐based studies on this topic are scarce. We evaluated the prevalence of psychotropic use and psychotropic polypharmacy in a Finnish nationwide cohort of people with intellectual disabilities aged 0–97 ...
Ville Virtanen, Leena Saastamoinen, Maria Arvio, Hannu T. Vesala, Sonja Miettinen, Antti Teittinen, Anna‐Maija Tolppanen   +6 more
wiley   +1 more source

Hypotension, the Infl uence of Mirtazapine in a Patient with Chronic Renal Failure

Turkish Journal of Nephrology, 2019
In patients with end-stage renal disease (ESRD), depression is the most commonly identifi ed psychiatric illness; however, its prevalence varies since it is assessed by using different methods in different studies and in different populations.
Demet YAVUZ, Rahman YAVUZ
doaj  

Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder

Neuropsychiatric Disease and Treatment, 2016
Takahiro Tsutsumi,1 Hiroko Sugawara,1,2 Ryoko Ito,1 Mizuho Asano,1 Satoru Shimizu,3 Jun Ishigooka,1 Katsuji Nishimura1 1Department of Psychiatry, 2Support Center for Women Health Care Professionals and Research, 3Department of Research, Medical Research
Tsutsumi T, Sugawara H, Ito R, Asano M, Shimizu S, Ishigooka J, Nishimura K   +6 more
doaj